Screening molecular markers for prediction of recurrence and prognosis of colorectal cancer.

筛选预测结直肠癌复发和预后的分子标志物。

• 批准号: 20390163
• 负责人: ISHIOKA Chikashi
• 金额: $ 11.32万
• 依托单位: Tohoku University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20390163/
• 关键词: 腫瘍検査学; 大腸癌; 抗がん剤感受性予測; 予後予測; 分子マーカー; 再発予測; 感受性予測

To identify gene sets for prediction of prognosis or for prediction of efficacy of anticancer drugs in metastatic colorectal cancer (mCRC), mRNA were extracted from tumor tissues of mCRC and were analyzed for oligonucleotide microarray. We found that mCRC were clustered into 3 large clusters. Further, these clusters were correlated with KRAS status and efficacy of chemotherapy with or without anti-EGFR antibody. We are now extracting gene sets for prediction of efficacy of specific anticancer drug or regimen.

为了确定转移性结直肠癌(MCRC)预后预测或抗癌药物疗效预测的基因集，从转移性结直肠癌组织中提取mRNA，并对其进行寡核苷酸芯片分析。我们发现mCRC被聚为3个大的簇。此外，这些簇与KRAS状态和使用或不使用抗EGFR抗体的化疗效果相关。我们现在正在提取基因集，用于预测特定抗癌药物或方案的疗效。

项目成果

Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.

• DOI: 10.1158/0008-5472.can-09-2850
• 发表时间: 2010-02-01
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Ransburgh DJ;Chiba N;Ishioka C;Toland AE;Parvin JD
• 通讯作者: Parvin JD

PROSPECTIVE COMPARISON OF SURGERY ALONE AND CHEMORADIOTHERAPY WITH SELECTIVE SURGERY IN RESECTABLE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS

• DOI: 10.1016/j.ijrobp.2009.02.086
• 发表时间: 2009-10-01
• 期刊: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
• 影响因子: 7
• 作者: Ariga, Hisanori;Nemoto, Kenji;Yamada, Shogo
• 通讯作者: Yamada, Shogo

alphaB-crystallin: A novel p53-target gene required for p53-dependent apoptosis

αB-晶状体蛋白：p53 依赖性细胞凋亡所需的新型 p53 靶基因

• 发表时间: 2009
• 期刊: Cancer Sci 100
• 作者: Watanabe;G.;Kato;S.;Nakata;H.;Ishida;T.;Ohuchi;N.;Ishioka;C
• 通讯作者: C

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

• DOI: 10.1007/s00280-008-0882-8
• 发表时间: 2009-07-01
• 期刊: CANCER CHEMOTHERAPY AND PHARMACOLOGY
• 影响因子: 3
• 作者: Ishida, Takanori;Kiba, Takayoshi;Ohuchi, Noriaki
• 通讯作者: Ohuchi, Noriaki

A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRl plus BV in patients (pts) with metastatic colorectal cancer (mCRC) : First report of T-CORE0702

一项随机试点研究，比较伊立替康加 S-1 (IRIS) 加贝伐单抗 (BV) 和改良 (m) FOLFIRl 加 BV 在转移性结直肠癌 (mCRC) 患者 (pts) 中的安全性和有效性：T-CORE0702 的第一份报告

• 发表时间: 2011
• 作者: Kato S;et al
• 通讯作者: et al